Skip to main content
Journal cover image

Rationale, design, and baseline characteristics of the virtual care to improve heart failure outcomes (VITAL-HF) trial.

Publication ,  Journal Article
Khan, MS; Sauer, AJ; Green, CL; McDermott, J; Khan, MS; Chaudhry, S-P; Haghighat, AR; Bennett, MK; Martyn, T; Shah, H; Govil, A; Stanis, T ...
Published in: Am Heart J
December 2025

BACKGROUND: Among patients with heart failure (HF), guideline-directed medical therapy (GDMT) remains underutilized. Remote digital interventions may facilitate rapid initiation and uptitration of GDMT; however, potential benefits have not been evaluated in well-powered trials. The VITAL-HF (Virtual Care to Improve Heart Failure Outcomes) trial assessed the safety and efficacy of a remote, digital intervention targeting GDMT optimization versus usual care in participants with HF with reduced ejection fraction (HFrEF). METHODS: VITAL-HF was a multicenter, randomized-controlled trial of 178 participants with HFrEF. Eligibility included smartphone access, English proficiency, and left ventricular ejection fraction ≤40%. Participants were randomized to receive either the remote, digital intervention (Story Health HF GDMT Titration Program) or usual care for 6 months. The primary outcome was change from baseline in GDMT using the HF Collaboratory Score (HFC), an expert-defined score integrating use and dose of prescribed GDMT. Secondary outcomes included healthcare visits related to symptomatic hypotension, hyperkalemia, and angioedema. RESULTS: The median age was 66.4 (Q1-Q3: 56.1-73.1) years and 38.8% were female. Major comorbidities included hypertension (71.3%), coronary artery disease (45.5%), atrial fibrillation/flutter (31.5%), and type 2 diabetes (28.1%). At enrollment, the median HFC score was 5 (Q1-Q3: 4-6) with 84.8% on an evidence-based beta blocker, 48.9% on an angiotensin receptor neprilysin inhibitor, 48.9% on a mineralocorticoid receptor antagonist, and 47.2% on a sodium-glucose cotransporter-2 inhibitor. CONCLUSIONS: The VITAL-HF trial results will provide valuable insights into the safety and efficacy of a remote, digital intervention to improve the use and intensification of GDMT for patients with HFrEF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05602454; ClinicalTrials.gov URL: https://clinicaltrials.gov/study/NCT05602454.

Duke Scholars

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

December 2025

Volume

290

Start / End Page

46 / 57

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Telemedicine
  • Stroke Volume
  • Randomized Controlled Trials as Topic
  • Multicenter Studies as Topic
  • Mineralocorticoid Receptor Antagonists
  • Middle Aged
  • Male
  • Humans
  • Heart Failure
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Khan, M. S., Sauer, A. J., Green, C. L., McDermott, J., Chaudhry, S.-P., Haghighat, A. R., … DeVore, A. D. (2025). Rationale, design, and baseline characteristics of the virtual care to improve heart failure outcomes (VITAL-HF) trial. Am Heart J, 290, 46–57. https://doi.org/10.1016/j.ahj.2025.06.001
Khan, Mirza S., Andrew J. Sauer, Cynthia L. Green, Jaime McDermott, Muhammad Shahzeb Khan, Sunit-Preet Chaudhry, Amir R. Haghighat, et al. “Rationale, design, and baseline characteristics of the virtual care to improve heart failure outcomes (VITAL-HF) trial.Am Heart J 290 (December 2025): 46–57. https://doi.org/10.1016/j.ahj.2025.06.001.
Khan MS, Sauer AJ, Green CL, McDermott J, Chaudhry S-P, Haghighat AR, et al. Rationale, design, and baseline characteristics of the virtual care to improve heart failure outcomes (VITAL-HF) trial. Am Heart J. 2025 Dec;290:46–57.
Khan, Mirza S., et al. “Rationale, design, and baseline characteristics of the virtual care to improve heart failure outcomes (VITAL-HF) trial.Am Heart J, vol. 290, Dec. 2025, pp. 46–57. Pubmed, doi:10.1016/j.ahj.2025.06.001.
Khan MS, Sauer AJ, Green CL, McDermott J, Chaudhry S-P, Haghighat AR, Bennett MK, Martyn T, Shah H, Govil A, Stanis T, Albert NM, DeVore AD. Rationale, design, and baseline characteristics of the virtual care to improve heart failure outcomes (VITAL-HF) trial. Am Heart J. 2025 Dec;290:46–57.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

December 2025

Volume

290

Start / End Page

46 / 57

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Telemedicine
  • Stroke Volume
  • Randomized Controlled Trials as Topic
  • Multicenter Studies as Topic
  • Mineralocorticoid Receptor Antagonists
  • Middle Aged
  • Male
  • Humans
  • Heart Failure